Poussot Rodolphe Jean 4

What Happened

• Rodolphe Jean Poussot, SVP, Strategy & Corporate Development at West Pharmaceutical Services (WST), was granted two derivative equity awards on 2026-03-01: 437 restricted stock units (RSUs) and 1,040 award/option units. Both awards show an acquisition price of $0.00 (typical for compensation grants) and are reported as derivative holdings rather than open‑market purchases or sales. These awards do not represent immediately tradable shares; value will depend on future vesting and, for options, any exercise.

Key Details

• Transaction date: 2026-03-01; Form 4 filed: 2026-03-03 (timely).
• Price: $0.00 for both grants (compensation awards).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnotes:
  • F1: Each restricted stock unit represents a contingent right to receive one share of WST common stock.
  • F2: The restricted stock units vest in four equal annual installments beginning March 1, 2027.
  • F3: The stock option vests in four equal annual installments beginning March 1, 2027.
• Transaction code: A = Award/Grant (derivative), not a purchase (P) or sale (S).

Context

• RSUs convert to actual shares only as they vest (no immediate ownership). Stock options must vest and then be exercised (and possibly paid for) to convert to shares; they are not the same as immediately owned stock. Compensation grants like these are common for executives and do not by themselves indicate buying or selling sentiment.